Aardvark Therapeutics, Inc.
AARDDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How AARD's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARD-101 | Phase 3 | Hyperphagia | - | - |
Low Dose ARD-501 | Phase 2 | Autism Spectrum Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aardvark Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Aardvark Therapeutics, Inc.'s (AARD) pipeline across Phase 3, Phase 2. Its lead program is ARD-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aardvark Therapeutics, Inc.'s next FDA catalyst?→
Aardvark Therapeutics, Inc.'s (AARD) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AARD biotech catalysts?→
Add AARD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aardvark Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.